X-Seal EU Post-Market Clinical Follow-Up Protocol

Inclusion Criteria: * Candidate for non-emergent diagnostic or interventional cardiac catheterization via a femoral sheath ≤6F. * Age ≥18 years. * Understand and sign the study specific written informed consent form. * In the investigator's opinion, the patient is suitable for the X-Seal vascular closure device, conventional hemostasis techniques and participation in an investigational trial. * Eligible for sheath removal in the catheterization lab. Exclusion Criteria: * Patients who are known to be pregnant or lactating. * Patients who are immunocompromised. * Prior target artery closure with any vascular closure device or closure with manual compression win 30 days prior to this procedure. * Patients with significant anemia (hemoglobin \<10 g/DL, Hct\<30). * Patients who are morbidly obese or cachectic (BMI \>40 or \<20 kg/m2). * Patients with Systolic Blood Pressure \>180 mmHg, unless Systolic Pressure can be lowered by pharmacological agents prior to closure * Patients who are currently participating in another clinical trial of an investigational drug or device that has not concluded the follow-up period. * Patients with a baseline INR \> 1.5 (e.g. coumadin therapy). * Patients with a known bleeding disorder including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand's disease. * Patients with small femoral arteries (\<4 mm), femoral artery stenosis resulting in a vessel diameter \<4 mm, or patients with severe peripheral vascular disease. * Patients with puncture site believed to be in the profunda femoris, superficial femoral artery, or at the bifurcation of the arteries. * Common femoral artery with fluoroscopically visible calcium. * Femoral arteries that are suspected to have experienced a back wall puncture or that underwent \>one (1) arterial puncture during the catheterization procedure. * Patients having a complication(s) at the femoral artery access site pre-sheath removal including hematoma, pseudoaneurysm, or arterio-venous fistula. * Patients in whom continued heparin or other anticoagulant/antiplatelet therapy is planned (with the exception of Glycoprotein IIb/IIIa receptor blockers) following completion of the catheterization procedure. * Patients whose ACT is \>300 seconds prior to removal of the guiding catheter. * Patients who cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence or life threatening disease. * Prior femoral vascular surgery or vascular graft in region of access site. * Patient is unable to ambulate at baseline. * Acute ST-elevation MI within 48 hours prior to procedure. * Active systemic or cutaneous infection or inflammation * Patients with unilateral or bilateral lower extremity amputation * Patients with renal insufficiency (serum creatinine \>2.5 mg/dl) * Patients with marked tortuosity of the femoral or iliac artery * Patients in whom bacterial contamination of the procedure sheath or surrounding tissues may have occurred as this may result in infection * Patients in whom the puncture site is located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks, since such a puncture site may result in a retroperitoneal hematoma/bleed. Perform a femoral angiogram to verify the location of the puncture site * Patients with known allergies to beef products, collagen and/or collagen products, or polyglycolic or polylactic acid polymers * Patients with known allergy to stainless steel or nickel. See MRI information in the IFU. * Patients undergoing therapeutic thrombolysis * Patients punctured through a vascular graft